The South Korean pharma industry is beginning to feel the fallout from the prolonged national walkout by trainee doctors that began in February.
Korea Q1 Roundup: Pharma Begins To Feel Impact From Doctors’ Walkout
Mainstays Generally Strong
As South Korea's doctors continue their long-running protest against a government plan to raise the medical student quota at universities, the walk-outs may be beginning to take a toll on the pharma industry, with many large firms reporting weak earnings in the last quarter.

More from South Korea
South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.
A new report from a domestic institute on South Korea’s biopharma M&A trends shows a pickup in activity, but that this remains relatively weak and small-scale. It calls for broader domestic government support to build expertise, drive innovation and globalization.
Cross-Asian initiative has already brought several South Korean gene and cell therapy startups and Japanese VCs closer, with further hopes for product development and launches in Japan, regulatory harmonization and gliobalization.
The latest activity in the South Korean biotech sector includes IPOs by Orum and Dongkook Life, as well as progress with ADCs at multiple firms.